Novo Nordisk and Eli Lilly are duking it out in the market, but dozens of competitors are waiting in the wings.

Despite the astounding efficacy and commercial potential of incretins in obesity, many groups are trying different mechanistic approaches to the disease – if only to enable combinations. 

CEO Thomas Feldthus's new broom is sweeping clean at Saniona with the closure of its US operations and an aim of exploiting the significant interest being shown across its pipeline programs.

Sio Gene, Genocea, Solid Biosciences, Saniona and Black Diamond join First Wave, Zosano, Vallon, Finch, Magenta, ProQR and Imara on the growing list of biopharma firms reducing headcount to make their cash last until valuations return to a level that may support new fundraising.